EDCTP contributed to controlling the spread of AMR throughout its first programme (2003-2014), and continues to do so under its second programme (2014-2024), by providing support for projects which:
- strengthen laboratory capacity;
- support and improve processes in the drug regulatory environment;
- strengthen capacity for pharmacovigilance; and
- support the establishment of collaborative research groups working on drug resistance.
EDCTP prioritises research efforts to identify diagnostics and appropriate treatment for poverty-related infectious diseases affecting sub-Saharan Africa, including strains of pathogens which are drug resistant. Efforts to support pharmacovigilance capacity are also made in view of the need for more knowledge on AMR through surveillance in affected countries. As suggested by experts in the January 2017 report of the Uppsala Monitoring Centre, pharmacovigilance tools can play an important role in tackling AMR.
In the first years of the second EDCTP programme (EDCTP2) several projects with a specific focus on antimicrobial resistance have been funded. These projects can be found via the public portal of the EDCTP grants management system and include:
Children with HIV in Africa – pharmacokinetics and acceptability of simple antiretroviral regimens (CHAPAS-4). Project coordinator: Dr Mutsa Bwakura-Dangarembizi.
Low frequent HIV drug resistant polymorphisms in infants born to HIV seropositive mothers: implications on response to therapy (HIVDR). Senior Fellow: Dr Immaculate Nankya.
Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy in Cameroon: The READY-Study. Career Development Fellow: Dr Joseph Fokam.
Culture free diagnosis and follow-up of multidrug resistant tuberculosis patients (DIAMA). Project coordinator: Dr Dissou Affolabi.
Novel biomarkers predictive of susceptibility and treatment response in patients with MDR-TB (DTB). Senior Fellow: Prof. Keertan Dheda.
Optimising linezolid use for drug-resistant tuberculosis in South Africa: the effects of linezolid exposure on toxicity, treatment response, and linezolid resistance (Linezolid for DR-TB in South Africa). Career Development Fellow: Dr Sean Wasserman.
Biomarker profile predicting unsuccessful treatment response in patients with MDR-TB (BTR-TB). Career Development Fellow: Dr Ali Esmail.
IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi, and Tanzania (IMPROVE). Prof. Feiko ter Kuile.
IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in HIV-infected pregnancy in Kenya and Malawi: a multicentre 3-arm placebo-controlled trial (IMPROVE-2). Prof. Feiko ter Kuile.
Determinants and prevalence of parasite resistance among pregnant women receiving Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) in a malaria endemic community (IPTp-SP resistance in Nigeria) (Career Development Fellow: Dr Atinuke Olaleye.
EDCTP-supported research networks
EDCTP regional Networks of Excellence have also conducted important work within the AMR sphere; for example, WANETAM established laboratory capacity and provided essential data on the extent of drug resistant tuberculosis in eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo).
In 2016, EDCTP called for proposals which aimed to support the establishment of multidisciplinary consortia able to provide accelerated evidence for the optimal clinical management of patients and for guiding the public health response to any severe infectious outbreak caused by pathogens within the scope of the EDCTP programme with pandemic potential or that may cause significant damage to health and socio-economics in Africa (including antimicrobial-resistant pathogens). The awardees are expected to have an impact on research capacity preparedness, and design of optimal prevention and clinical management strategies. Two networks have been identified through this call and the grant agreements are expected to be signed soon.